Novo Nordisk A/S
NYSE:NVO
Intrinsic Value
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. [ Read More ]
The intrinsic value of one NVO stock under the Base Case scenario is 88.5 USD. Compared to the current market price of 122.75 USD, Novo Nordisk A/S is Overvalued by 28%.
Valuation Backtest
Novo Nordisk A/S
Run backtest to discover the historical profit from buying and selling NVO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Novo Nordisk A/S
Current Assets | 139.6B |
Cash & Short-Term Investments | 30.2B |
Receivables | 75.3B |
Other Current Assets | 34.2B |
Non-Current Assets | 174.8B |
Long-Term Investments | 1.7B |
PP&E | 91B |
Intangibles | 60.4B |
Other Non-Current Assets | 21.8B |
Current Liabilities | 169.7B |
Accounts Payable | 25.6B |
Other Current Liabilities | 144B |
Non-Current Liabilities | 38.3B |
Long-Term Debt | 20.5B |
Other Non-Current Liabilities | 17.7B |
Earnings Waterfall
Novo Nordisk A/S
Revenue
|
232.3B
DKK
|
Cost of Revenue
|
-35.8B
DKK
|
Gross Profit
|
196.5B
DKK
|
Operating Expenses
|
-91.8B
DKK
|
Operating Income
|
104.7B
DKK
|
Other Expenses
|
-21B
DKK
|
Net Income
|
83.7B
DKK
|
Free Cash Flow Analysis
Novo Nordisk A/S
What is Free Cash Flow?
NVO Profitability Score
Profitability Due Diligence
Novo Nordisk A/S's profitability score is 86/100. The higher the profitability score, the more profitable the company is.
Score
Novo Nordisk A/S's profitability score is 86/100. The higher the profitability score, the more profitable the company is.
NVO Solvency Score
Solvency Due Diligence
Novo Nordisk A/S's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Novo Nordisk A/S's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVO Price Targets Summary
Novo Nordisk A/S
According to Wall Street analysts, the average 1-year price target for NVO is 133.89 USD with a low forecast of 77.99 USD and a high forecast of 168.28 USD.
Shareholder Return
NOVO B Price
Novo Nordisk A/S
Average Annual Return | 36.42% |
Standard Deviation of Annual Returns | 24.56% |
Max Drawdown | -7% |
Market Capitalization | 3.8T DKK |
Shares Outstanding | 4 462 427 800 |
Percentage of Shares Shorted |
N/A
|
NVO News
Last Important Events
Novo Nordisk A/S
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Novo Nordisk A/S
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Contact
IPO
Employees
Officers
The intrinsic value of one NVO stock under the Base Case scenario is 88.5 USD.
Compared to the current market price of 122.75 USD, Novo Nordisk A/S is Overvalued by 28%.